Dinko Bismarck, Awuah Dennis, Boampong Kwadwo, Larbi John A, Bousema Teun, Sutherland Colin J
Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.
Department of Theoretical and Applied Biology, Faculty of Biosciences, College of Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Parasite Epidemiol Control. 2023 Feb 17;21:e00292. doi: 10.1016/j.parepi.2023.e00292. eCollection 2023 May.
Asymptomatic Plasmodium carriers form the majority of malaria-infected individuals in most endemic areas. A proportion of these asymptomatically infected individuals carry gametocytes, the transmissible stages of malaria parasites, that sustain human to mosquito transmission. Few studies examine gametocytaemia in asymptomatic school children who may form an important reservoir for transmission. We assessed the prevalence of gametocytaemia before antimalarial treatment and monitored clearance of gametocytes after treatment in asymptomatic malaria children.
A total of 274 primary school children were screened for parasitaemia by microscopy. One hundred and fifty-five (155) parasite positive children were treated under direct observation with dihydroartemisinin-piperaquine (DP). Gametocyte carriage was determined by microscopy seven days prior to treatment, day 0 before treatment, and on days 7, 14 and 21 post initiation of treatment.
The prevalence of microscopically-detectable gametocytes at screening (day -7) and enrolment (day 0) were 9% (25/274) and 13.6% (21/155) respectively. Following DP treatment, gametocyte carriage dropped to 4% (6/135), 3% (5/135) and 6% (10/151) on days 7, 14 and 21 respectively. Asexual parasites persisted in a minority of treated children, resulting in microscopically detectable parasites on days 7 (9%, 12/135), 14 (4%, 5/135) and 21 (7%, 10/151). Gametocyte carriage was inversely correlated with the age of the participants ( = 0.05) and asexual parasite density ( = 0.08). In a variate analysis, persistent gametocytaemia 7 or more days after treatment was significantly associated with post-treatment asexual parasitaemia at day 7 ( = 0.027) and presence of gametocytes on the day of treatment ( < 0.001).
Though DP provides both excellent cure rates for clinical malaria and a long prophylactic half-life, our findings suggest that after treatment of asymptomatic infections, both asexual parasites and gametocytes may persist in a minority of individuals during the first 3 weeks after treatment. This indicates DP may be unsuitable for use in mass drug administration strategies towards malaria elimination in Africa.
在大多数疟疾流行地区,无症状疟原虫携带者占感染疟疾个体的大多数。这些无症状感染个体中有一部分携带配子体,即疟原虫的可传播阶段,维持着人到蚊子的传播。很少有研究调查无症状学龄儿童中的配子体血症情况,而这些儿童可能是重要的传播储存宿主。我们评估了无症状疟疾儿童在抗疟治疗前配子体血症的患病率,并监测了治疗后配子体的清除情况。
通过显微镜检查对总共274名小学生进行了寄生虫血症筛查。155名寄生虫检测呈阳性的儿童在直接观察下接受双氢青蒿素 - 哌喹(DP)治疗。在治疗前7天、治疗前第0天以及治疗开始后的第7天、第14天和第21天,通过显微镜检查确定配子体携带情况。
筛查时(第 -7天)和入组时(第0天)显微镜下可检测到的配子体患病率分别为9%(25/274)和13.6%(21/155)。DP治疗后,在第7天、第14天和第21天,配子体携带率分别降至4%(6/135)、3%(5/135)和6%(10/151)。少数接受治疗的儿童中无性寄生虫持续存在,导致在第7天(9%,12/135)、第14天(4%,5/135)和第21天(7%,10/151)显微镜下可检测到寄生虫。配子体携带率与参与者年龄呈负相关(r = 0.05),与无性寄生虫密度呈负相关(r = 0.08)。在多变量分析中,治疗后7天或更长时间持续存在的配子体血症与治疗后第7天的无性寄生虫血症(P = 0.027)以及治疗当天存在配子体显著相关(P < 0.001)。
尽管DP对临床疟疾具有出色的治愈率和较长的预防半衰期,但我们的研究结果表明,在治疗无症状感染后,无性寄生虫和配子体可能在少数个体中在治疗后的前3周内持续存在。这表明DP可能不适用于非洲消除疟疾的大规模药物给药策略。